# A Study to Evaluate Safety and Tolerability of Different Doses and Efficacy of PQ912 in Subjects With MCI and Mild AD

> **NCT04498650** · PHASE2 · COMPLETED · sponsor: **Vivoryon Therapeutics N.V.** · enrollment: 259 (actual)

## Conditions studied

- Early Alzheimers Disease
- Mild Cognitive Impairment Due to AD

## Interventions

- **DRUG:** PQ912
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04498650
- **Lead sponsor:** Vivoryon Therapeutics N.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-06
- **Primary completion:** 2023-12-18
- **Final completion:** 2024-01-12
- **Target enrollment:** 259 (ACTUAL)
- **Last updated:** 2024-03-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04498650

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04498650, "A Study to Evaluate Safety and Tolerability of Different Doses and Efficacy of PQ912 in Subjects With MCI and Mild AD". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04498650. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*